ALKS - Alkermes plc

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
50.58
+0.02 (+0.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close50.56
Open50.54
Bid41.09 x 100
Ask52.48 x 200
Day's Range50.08 - 50.84
52 Week Range48.90 - 63.40
Volume809,148
Avg. Volume696,036
Market Cap7.77B
Beta2.31
PE Ratio (TTM)-39.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markityesterday

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 18. Index (PMI) data, output in the Healthcare sector is rising.

  • Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 18, 2017
    Capital Cube3 days ago

    Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 18, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alkermes Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Capital Cube15 days ago

    Alkermes Plc – Value Analysis (NASDAQ:ALKS) : October 6, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alkermes Plc a score of 31. Our analysis is based on comparing Alkermes Plc with the following peers – Acorda Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Sanofi Sponsored ADR, Zogenix, Inc., Pfizer Inc. and Astrazeneca ... Read more (Read more...)

  • Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 5, 2017
    Capital Cube16 days ago

    Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 5, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alkermes Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Barrons.com17 days ago

    [$$] 6 Top Pharma Picks for Q4

    Credit Suisse In the final quarter of 2017, we anticipate investors will continue to keep an eye on macro issues such as U.S. drug pricing and potential U.S. corporate tax reform, although a significant amount of product news should also impact how investors view the various names. Overall, we believe sentiment on the group remains relatively robust with noise on the drug pricing side far below what it has been and investors still cautiously optimistic on the possibility of corporate tax reform coming through in 2018. Depending on how these issues play out, it could also lead to increased excitement around potential business development and mergers and acquisitions (M&A) in the sector, as we believe most of our large cap companies are still waiting for further clarity on these issues before announcing transformative deals.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit23 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 26. Over the last one-month, outflows of investor capital in ETFs holding ALKS totaled $334 million.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit29 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 20. Index (PMI) data, output in the Healthcare sector is rising.

  • Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
    Zackslast month

    Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

    Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Alkermes PLC.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on September 14. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 25. Index (PMI) data, output in the Healthcare sector is rising.

  • Barrons.comlast month

    [$$] Merck Tops JNJ, Allergan

    Credit Suisse As we wrap up the third quarter, we anticipate the focus for the rest of the year will continue to be macro questions/pressures and a limited number of fundamental catalysts that could change sentiment on the U.S. pharmaceuticals sector as a whole. Positive product news may provide opportunities for upside, although we believe this may be balanced out by fewer impactful pipeline readouts in the latter part of 2017 and continued debates around drug pricing. As we approach the fourth quarter, while Gilead Sciences’ (GILD) recent acquisition of Kite Pharma’s (KITE) has improved investor sentiment on the broader biopharma space, we note most of our large-cap companies seem to be waiting for further clarity around tax reform before announcing meaningful deals.

  • Barrons.comlast month

    Three Pharma Stocks To Buy As 2017 Ends With A Whimper

    As the third quarter draws to a close, Credit Suisse's Vamil Divan and his team check in with the pharmaceutical sector, writing that the rest of the year will be dominated by macro questions and pressures and a limited number of fundamental catalysts. Certainly, positive product news could provide some opportunities for upside, but Divan warns that these will be balanced out by fewer impactful pipeline readouts, along with continued debates about drug pricing. Going into the fourth quarter, Divan writes that while Gilead's (GILD) acquisition of Kite Pharma (KITE) has improved investor sentiment in biotech, most large cap companies appear to be waiting for further clarity about tax reform before going ahead with major deals.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 25. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 25. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 25. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe
    Zacks2 months ago

    Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe

    Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.

  • Alkermes Initiates Rolling Submission of Depression Drug
    Zacks2 months ago

    Alkermes Initiates Rolling Submission of Depression Drug

    Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALKS totaled $71 million.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Capital Cube2 months ago

    ETFs with exposure to Alkermes Plc : August 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alkermes Plc Here are 5 ETFs with the largest exposure to ALKS-US. Comparing the performance and risk of Alkermes Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALKS earnings conference call or presentation 27-Jul-17 12:30pm GMT

    Q2 2017 Alkermes Plc Earnings Call

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • IHS Markit Score downgrades Alkermes PLC to 63 out of 100, ranking positively in only one out of three available IHS Markit categories.
    Markit2 months ago

    IHS Markit Score downgrades Alkermes PLC to 63 out of 100, ranking positively in only one out of three available IHS Markit categories.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.